# Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

> **NCT03313544** · PHASE4 · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma
- Non-small Cell
- Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DEVICE:** MRI
- **BIOLOGICAL:** BLOOD SAMPLES
- **DEVICE:** trans-thoracic echocardiography

## Key facts

- **NCT ID:** NCT03313544
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-09
- **Primary completion:** 2024-10
- **Final completion:** 2025-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03313544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03313544, "Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03313544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*